LivingGLP1
Descriptive only

Acute kidney injury

Overweight or obesity without diabetes (adults)

longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)
7
Randomized trials
21
Treatments
4,181
Participants
14
Events

In plain language

No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 7 trials. The trial data below are shown as reported.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
ALENIG_PO_120MG_QDALENIG_PO_45MG_QDALENIG_PO_90MG_QDBIMASEMA_SC_1p0-10MG_QWBIMASEMA_SC_1p0-30MG_QWBIMASEMA_SC_2p4-10MG_QWBIMASEMA_SC_2p4-30MG_QWEXENER_SC_2-10MG_QWLOTI_PO_140MG_QDLOTI_PO_160MG_QDLOTI_PO_200MG_QDLOTI_PO_20MG_QDLOTI_PO_260MG_QDLOTI_PO_40MG_QDLOTI_PO_80MG_QDMAZD_SC_16MG_QWOTHER_ACTIVE_bimagrumabPLACEBOSEMA_PO_14MG_QDSEMA_SC_1p0MG_QWSEMA_SC_2p4MG_QW
Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
  • NoteOutcome assessment, time point: selected time points span 24 to 104 weeks
  • NoteOutcome assessment, intercurrent events (discontinuation): mixed: not stated 6, while_on_treatment 1
  • NoteOutcome assessment, intercurrent events (rescue): mixed: not stated 6, treatment_policy 1
  • NoteRisk of bias, blinding: mixed: double_blind 6, open_label 1
  • NoteData handling, input conversions: arms_combined 5, nonserious_only 16
Comparability items per trial
Trialtime weeksanalysis setdefinitioninstrumentadjudicatedproportion methodintercurrent events (discontinuation)intercurrent events (rescue)blindingfundingstart yearEligibility
STEP 175safetynot statednot statednot statednot statedwhile_on_treatmenttreatment_policydouble_blindindustry2018adults; BMI 30 or more, or 27 or more with a weight related condition; no diabetes; HbA1c below 6.5 percent
NCT0557997728safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2022age 18 to 75; T2D cohort on metformin, HbA1c 7.0 to 10.0, BMI 23 or more; obesity cohort BMI 30 or more without diabetes
NCT05616013104safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2022adults 18 to 80; BMI 30 or more, or 27 or more with comorbidity; no diabetes (HbA1c below 6.5 percent); weight below 150 kg
ACCESS36safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2024age 18 to 79; BMI 30 or more, or 27 or more with comorbidity; HbA1c below 6.5 percent; weight above 80 kg; no diabetes
STEP 375safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2018BMI 30 or more, or 27 with comorbidity; no type 2 diabetes
Dapalost24safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2014age 18 to 70; BMI 30 to 45 kg/m2; no diabetes
NCT0562383927safetynot statednot statednot statednot statednot statednot stateddouble_blindindustry2022age 18 to 70; BMI 27 to 50; HbA1c below 6.5 percent; no diabetes

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
Trial data entering this analysis
TrialArmTreatmentWeekDataValueSEEvents / NFlagsSource
STEP 1A1SEMA_SC_2p4MG_QW75arm, events3 / 1,306R0023399:Table 3
STEP 1A2PLACEBO75arm, events2 / 655R0023399:Table 3
NCT05579977A1+A8PLACEBO28arm, events0 / 139nonserious_only;arms_combinedregistry:adverse_events
NCT05579977A10LOTI_PO_140MG_QD28arm, events0 / 64nonserious_onlyregistry:adverse_events
NCT05579977A11+A12LOTI_PO_200MG_QD28arm, events0 / 131nonserious_only;arms_combinedregistry:adverse_events
NCT05579977A13+A6LOTI_PO_260MG_QD28arm, events0 / 138nonserious_only;arms_combinedregistry:adverse_events
NCT05579977A2LOTI_PO_20MG_QD28arm, events0 / 73nonserious_onlyregistry:adverse_events
NCT05579977A3LOTI_PO_40MG_QD28arm, events3 / 72nonserious_onlyregistry:adverse_events
NCT05579977A4+A9LOTI_PO_80MG_QD28arm, events0 / 139nonserious_only;arms_combinedregistry:adverse_events
NCT05579977A5LOTI_PO_160MG_QD28arm, events0 / 73nonserious_onlyregistry:adverse_events
NCT05579977A7SEMA_PO_14MG_QD28arm, events0 / 73nonserious_onlyregistry:adverse_events
NCT05616013A3OTHER_ACTIVE_bimagrumab104arm, events1 / 57nonserious_onlyregistry:adverse_events
NCT05616013A4SEMA_SC_1p0MG_QW104arm, events1 / 56nonserious_onlyregistry:adverse_events
NCT05616013A5SEMA_SC_2p4MG_QW104arm, events1 / 57nonserious_onlyregistry:adverse_events
NCT05616013A6BIMASEMA_SC_1p0-10MG_QW104arm, events0 / 56nonserious_onlyregistry:adverse_events
NCT05616013A7BIMASEMA_SC_2p4-10MG_QW104arm, events0 / 56nonserious_onlyregistry:adverse_events
NCT05616013A8BIMASEMA_SC_1p0-30MG_QW104arm, events0 / 56nonserious_onlyregistry:adverse_events
NCT05616013A9BIMASEMA_SC_2p4-30MG_QW104arm, events0 / 57nonserious_onlyregistry:adverse_events
ACCESSA1ALENIG_PO_45MG_QD36arm, events0 / 45R0000892:Extended Data Table 1
ACCESSA2ALENIG_PO_90MG_QD36arm, events0 / 65R0000892:Extended Data Table 1
ACCESSA3ALENIG_PO_120MG_QD36arm, events3 / 64R0000892:Extended Data Table 1
ACCESSA4PLACEBO36arm, events0 / 56R0000892:Extended Data Table 1
STEP 3A1SEMA_SC_2p4MG_QW75arm, events0 / 407R0020858:Table 2
STEP 3A2PLACEBO75arm, events0 / 204R0020858:Table 2
DapalostA1EXENER_SC_2-10MG_QW24arm, events0 / 25R0025627:Table 3
DapalostA2PLACEBO24arm, events0 / 25R0025627:Table 3
NCT05623839A1PLACEBO27arm, events0 / 8R0013210:Supplement Table S2
NCT05623839A2+A3MAZD_SC_16MG_QW27arm, events0 / 24arms_combinedR0013210:Supplement Table S2

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab